Elucidata Home

Harness the power of ML-ready data
for insight discovery

Our cloud-based platform Polly, delivers richly curated biomedical molecular data  prepared for machine learning applications

Curating ML-ready data at scale
517106
Datasets
34281809
Samples
5841
Diseases
50
Sources
Enabling integrative data analysis across 20+ data types

Providing access to analysis-ready data from multiple sources in one place​

Our curation infrastructure processes public as well as proprietary data through a standard pipeline, producing analysis-ready data suitable for machine learning applications.

How does Polly make data ML-ready?

Metadata breadth and depth

A plethora of rich metadata annotations with scientific context enable you to find the data most relevant to your research.

Metadata accuracy

Our ML-based curation infrastructure maps metadata with accuracy matching that of human experts.

Data processing

Raw data is normalized into a standard and consistent format, allowing you to focus on data analysis and interpretation.

Read More
Data on Polly is organized as OmixAtlases
Read More
Rich metadata annotations help you find relevant datasets within seconds on OmixAtlas
Read More
Perform advanced querying through code across 300,000+ datasets on Polly or on your computational platform
Read More
Workspaces on Polly helps you reduce clutter and organize all your data for easy access and seamless sharing
Previous
Next

Leverage code-first approaches to extract deeper insights from data

Perform advanced querying on data through code

  • Polly Libraries facilitates powerful querying capabilities through code, allowing in-depth data exploration.

Take Polly where you work

  • Access data on your preferred computational infrastructure through Libraries.
  • Integrate data on Polly with analytical platforms including AWS Sagemaker and Databricks.

How it works

Keen to know how we help data-driven drug discovery teams get to faster actionable insights?

What our partners have to say

Best practices for data-driven drug discovery